点击次数：

论文类型：期刊论文

发表时间：2019-05-07

发表刊物：CANCER CELL INTERNATIONAL

收录刊物：PubMed、SCIE

卷号：19

期号：1

页面范围：122

ISSN号：1475-2867

关键字：Acute myeloid leukemia; miR-25; Clinical outcome; Chemotherapy; Allo-HSCT

摘要：BackgroundAcute myeloid leukemia (AML) pertains to a hematologic malignancy with heterogeneous therapeutic responses. Improvements in risk stratification in AML patients are warranted. MicroRNAs have been associated with the pathogenesis of AML.MethodsTo examine the prognostic value of miR-25, 162 cases with de novo AML were classified into two groups according to different treatment regimens.ResultsIn the chemotherapy group, cases with upregulated miR-25 expression showed relatively longer overall survival (OS; P=0.0086) and event-free survival (EFS; P=0.019). Multivariable analyses revealed that miR-25 upregulation is an independent predictor for extended OS (HR=0.556, P=0.015) and EFS (HR=0.598, P=0.03). In addition, allogeneic hematopoietic stem cell transplantation (allo-HSCT) circumvented the poor prognosis that was related to miR-25 downregulation with chemotherapy. The expression level pattern of miR-25 coincided with AML differentiation and proliferation, which included HOXA and HOXB cluster members, as well as the HOX cofactor MEIS1. The MYH9 gene was identified as a direct target of miR-25.ConclusionsThe miR-25 levels are correlated with prognosis in AML independently of other powerful molecular markers. The expression of miR-25 may contribute to the selection of the optimal treatment regimen between chemotherapy and allo-HCST for AML patients.